Illumina, Inc.

WBAG:ILMN Stock Report

Market Cap: €19.9b

Illumina Valuation

Is ILMN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ILMN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ILMN (€127.16) is trading below our estimate of fair value (€143.87)

Significantly Below Fair Value: ILMN is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ILMN?

Key metric: As ILMN is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ILMN. This is calculated by dividing ILMN's market cap by their current revenue.
What is ILMN's PS Ratio?
PS Ratio4.9x
SalesUS$4.39b
Market CapUS$20.88b

Price to Sales Ratio vs Peers

How does ILMN's PS Ratio compare to its peers?

The above table shows the PS ratio for ILMN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average10.2x
WAT Waters
7.5x5.5%US$21.2b
WST West Pharmaceutical Services
8.1x6.9%US$22.6b
MTD Mettler-Toledo International
6.7x4.2%US$24.6b
DIVISLAB Divi's Laboratories
18.4x16.3%₹1.6t
ILMN Illumina
4.9x4.8%€20.9b

Price-To-Sales vs Peers: ILMN is good value based on its Price-To-Sales Ratio (4.9x) compared to the peer average (10.2x).

Price to Sales Ratio vs Industry

How does ILMN's PS Ratio compare vs other companies in the European Life Sciences Industry?

5 CompaniesPrice / SalesEstimated GrowthMarket Cap
ILMN 4.9xIndustry Avg. 4.2xNo. of Companies9PS03.26.49.612.816+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: ILMN is expensive based on its Price-To-Sales Ratio (4.9x) compared to the European Life Sciences industry average (4.2x).

Price to Sales Ratio vs Fair Ratio

What is ILMN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ILMN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4.9x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate ILMN's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ILMN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€127.16
€156.17
+22.8%
16.1%€241.00€113.86n/a25
Nov ’25€134.84
€144.38
+7.1%
19.0%€231.69€96.54n/a24
Oct ’25€114.36
€134.26
+17.4%
20.2%€226.72€94.47n/a23
Sep ’25€118.14
€133.35
+12.9%
19.3%€217.51€94.37n/a23
Aug ’25€113.66
€135.97
+19.6%
22.3%€223.46€92.34n/a22
Jul ’25€99.68
€137.50
+37.9%
22.3%€225.91€93.35n/a22
Jun ’25€95.41
€142.91
+49.8%
23.8%€232.51€91.90n/a22
May ’25€116.60
€147.50
+26.5%
23.0%€237.52€93.88n/a23
Apr ’25€128.32
€147.62
+15.0%
23.4%€238.03€78.42n/a22
Mar ’25€130.90
€147.40
+12.6%
23.4%€238.08€78.44n/a22
Feb ’25€132.86
€142.46
+7.2%
29.8%€238.21€73.86n/a24
Jan ’25€128.48
€135.04
+5.1%
32.4%€233.70€45.29n/a24
Dec ’24€97.87
€141.37
+44.4%
38.1%€239.69€46.10n/a21
Nov ’24€101.06
€185.69
+83.7%
24.0%€300.22€94.41€134.8421
Oct ’24€129.14
€200.90
+55.6%
25.4%€300.80€94.59€114.3621
Sep ’24€156.86
€205.60
+31.1%
19.2%€293.10€138.26€118.1421
Aug ’24€172.40
€214.38
+24.3%
17.7%€292.12€133.59€113.6620
Jul ’24€172.78
€224.40
+29.9%
17.5%€307.84€137.43€99.6819
Jun ’24€184.28
€224.65
+21.9%
17.7%€308.92€137.91€95.4119
May ’24€185.38
€223.10
+20.3%
17.5%€304.44€136.73€116.6019
Apr ’24€209.55
€225.47
+7.6%
16.2%€279.36€139.68€128.3220
Mar ’24€184.66
€226.95
+22.9%
16.8%€282.09€139.65€130.9020
Feb ’24€193.76
€229.12
+18.3%
16.2%€275.97€147.18€132.8620
Jan ’24€187.08
€241.69
+29.2%
19.4%€330.19€150.94€128.4818
Dec ’23€210.50
€249.18
+18.4%
19.3%€338.03€154.53€97.8716
Nov ’23€224.10
€263.17
+17.4%
18.9%€344.15€177.14€101.0616

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

IQVIA Holdings

US$34.7b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQVH

US$182.50

7D

-9.3%

1Y

-5.8%

Almirall

€1.8b

A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.

ALM

€8.27

7D

-2.8%

1Y

-1.4%

Teva Pharmaceutical Industries

US$19.0b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEVA

US$16.10

7D

-0.6%

1Y

85.9%